Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Service Users Report Psychiatric Professionals as the Least Helpful Factor in Quitting Antipsychotics
A new study published in Psychology and Psychotherapy: Theory, Research and Practice finds that psychiatrists and other doctors are the most unhelpful factor for...
Long-term Outcomes Better for Those Who Stop Taking Antipsychotics
Research undermines the prolonged use of antipsychotics in schizophrenia treatment, suggesting improved social functioning and quality of life with discontinuation.
Psych Drugs May Increase Likelihood of Death in Schizophrenia
The drugs, especially benzos and high doses of antipsychotics, led to an increased risk of death within five years. Antidepressants also did not reduce mortality.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
Case Studies Reveal Patient Empowerment Through Tapering Antipsychotics
A new study shows how different patients respond to tapering antipsychotic medication under expert guidance, highlighting personal empowerment and the complexities of withdrawal.
Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
Antipsychotics Increase Risk of Dementia; New Research Illuminates Why
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.
Youth Antipsychotic Use Linked to Increased Risk of Death within Five Years
Those aged 18-24 had an increased risk of death within five years on doses above 100 mg chlorpromazine equivalents.
Why Gradual Reduction of Antipsychotics Could Be Safer for Service Users
A new commentary published in Current Opinion in Psychiatry presents the case for slow tapering of antipsychotics. According to authors Mark Horowitz and Joanna...
Wunderink: Antipsychotics Can Be Tapered Safely Without Increasing Relapse Risk
Tapering antipsychotics slowly and with supported decision-making may improve care for patients with psychosis.
The Ethics of Antipsychotic Dose Reduction and Patient Rights
New research highlights the ethical responsibilities of clinicians in supporting patients who choose to reduce or discontinue antipsychotic medication.
Do Antipsychotics Protect Against Early Death? A Review of the Evidence
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
Contribution of Antipsychotics to Suicidality and Depression
Peter Lehmann reviews the contribution of antipsychotics to suicide and depression in schizophrenia in the current International Journal of Psychotherapy. Publications about the intrinsic effects of...
For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
Tapered Antipsychotic Withdrawal Mitigates Risk of Psychotic Symptoms
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.
Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
Researchers Warn of “Brain Atrophy” in Children Prescribed Antipsychotics
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Antipsychotics Lead to Worse Outcomes in First-Episode Psychosis
Those who did not get antipsychotics in the first month were almost twice as likely to be in recovery after five years.
Study Highlights Difficulty of Antipsychotic Withdrawal
New research finds insomnia, anxiety, and depression are common symptoms of antipsychotic withdrawal, highlighting difficulties of discontinuation.
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
The Rise of the Digital Asylum
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.
Antipsychotics Often Prescribed Without Informed Consent
New research reveals that patients are often not given fully informed consent before being prescribed antipsychotics.
The Case Against Antipsychotics
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
Scientists Clarify Risks of Augmenting with Antipsychotic Medications for Depression
The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.
